D. Johnson

发表

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

D. Levine, M. Åstrand, P. Katz, 2010, Alimentary pharmacology & therapeutics.

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6‐month, randomized, double‐blind, placebo‐controlled study of efficacy and safety

R. Shaker, N. Vakil, C. Hwang, 2001, Alimentary pharmacology & therapeutics.

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

G. Falk, P. Kahrilas, D. Johnson, 2000, Alimentary pharmacology & therapeutics.

The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment, Suggested disease management guidelines.

A. Fendrick, R. Sampliner, P. Kahrilas, 1996, Archives of internal medicine.

Medical therapy for gastroesophageal reflux disease.

D. Johnson, 1992, The American journal of medicine.

A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro‐oesophageal reflux disease

D. Johnson, M. Ryan, M. Doviak, 2005, Alimentary pharmacology & therapeutics.

Clinical trial: esomeprazole for moderate‐to‐severe nighttime heartburn and gastro‐oesophageal reflux disease‐related sleep disturbances

C. Hwang, K. Brown, D. Johnson, 2010, Alimentary pharmacology & therapeutics.

Medical Therapy of GERD: current state of the art.

D. Johnson, 1996, Hospital practice.

Relationship between symptom load of gastro‐oesophageal reflux disease and health‐related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort

P. Wahlqvist, M. Wallander, J. Carlsson, 2008, Alimentary pharmacology & therapeutics.

Sleep dysfunction in patients with gastro‐oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study

J. C. Ware, D. Johnson, M. Tabangin, 2004, Alimentary pharmacology & therapeutics.

D. Johnson, W. Ruffin, 1996, Gastrointestinal endoscopy clinics of North America.

Systematic review: the burden of disruptive gastro‐oesophageal reflux disease on health‐related quality of life

J. Tack, D. Johnson, A. Becher, 2012, Alimentary pharmacology & therapeutics.

Symptoms of gastro‐oesophageal reflux disease and the severity of obstructive sleep apnoea syndrome are not related in sleep disorders center patients

R. Vorona, D. Johnson, M. Doviak, 2005, Alimentary pharmacology & therapeutics.

The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment

A. Fendrick, R. Sampliner, D. A. Lieberman, 1996 .

Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies

L. Laine, D. Johnson, M. Goldstein, 2011, Alimentary pharmacology & therapeutics.

Randomised clinical trial: the 5‐HT4 agonist revexepride in patients with gastro‐oesophageal reflux disease who have persistent symptoms despite PPI therapy

P. Malfertheiner, N. Shaheen, M. Ruth, 2015, Alimentary pharmacology & therapeutics.

Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose

T. Schall, S. Miao, J. Jaén, 2011, Clinical pharmacology and therapeutics.